Pharmaceutical Shifts: Sanofi’s Strategic Stake Sale, Supernus Setbacks, and Gilead’s Groundbreaking Advances February 19, 2025
Biogen Secures Exclusive Rights to Experimental Epilepsy Drug Zorevunersen, Targeting Breakthrough in Rare Neurological Disorders February 19, 2025
Biogen Expands Rare Disease Portfolio with Promising Dravet Syndrome Treatment Zorevunersen in $165 Million Deal February 19, 2025
Biogen Joins Forces with Stoke Therapeutics to Advance Innovative Epilepsy Treatment, Zorevunersen February 19, 2025
Biogen Secures Exclusive Rights to Innovative Dravet Syndrome Treatment in $165 Million Strategic Deal February 18, 2025
Biogen Strikes $165 Million Deal to Commercialize Groundbreaking Dravet Syndrome Treatment zorevunersen February 18, 2025
Revolutionizing Support: How Comprehensive Assistance Programs Transform Lives for Patients with Rare Diseases February 18, 2025
Navigating the Biotech IPO Landscape: Insights from Industry Leaders on Strategy and Success February 17, 2025
